IC
MRNA icon

Ikarian Capital’s Moderna MRNA Stock Holding History

Ikarian Capital’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-100,000
Closed -$4.16M – 197
2024
Q4 		$4.16M Buy
+100,000
New +$4.78M 0.57% 47
2024
Q1 		– Sell
-44,300
Closed -$4.41M – 166
2023
Q4 		$4.41M Buy
44,300
+41,857
+1,713% +$3.52M 0.41% 65
2023
Q3 		$25.2M Buy
+2,443
New +$273K 3.04% 8
2021
Q2 		– Sell
-600,000
Closed -$78.6M – 257
2021
Q1 		$78.6M Sell
600,000
-850,000
-59% -$123M 2.64% 6
2020
Q4 		$151M Buy
1,450,000
+356,100
+33% +$36M 6.68% 1
2020
Q3 		$77.4M Buy
1,093,900
+793,900
+265% +$55.4M 5.6% 3
2020
Q2 		$19.3M Buy
+300,000
New +$16.4M 1.53% 13

Other funds holding MRNA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Ikarian Capital's MRNA Position: Q1 2024 in Review

Ikarian Capital sold out of Moderna (MRNA) in Q1 2024, closing a stake of 24,546 shares — an estimated $2.44M sold.

Ikarian Capital first reported a position in MRNA in Q4 2020 and held it in 2 quarters. The position peaked at $6.48M in Q4 2020. 902 funds tracked by Wall St. Rank hold MRNA as of Q1 2024.

  • Ikarian Capital reported no remaining Moderna position as of Q1 2024 after selling out during the quarter.
  • Ikarian Capital sold 24,546 Moderna shares in Q1 2024, an estimated $2.44M.
  • Ikarian Capital first reported a position in Moderna in Q4 2020 and held it in 2 quarters.
  • Ikarian Capital's Moderna position peaked at $6.48M in Q4 2020.
  • 902 funds tracked by Wall St. Rank held Moderna as of Q1 2024.

Based on Ikarian Capital's 13F filing for Q1 2024, filed 15 May 2024.